PE20191656A1 - Inhibidores de ip6k - Google Patents
Inhibidores de ip6kInfo
- Publication number
- PE20191656A1 PE20191656A1 PE2019001965A PE2019001965A PE20191656A1 PE 20191656 A1 PE20191656 A1 PE 20191656A1 PE 2019001965 A PE2019001965 A PE 2019001965A PE 2019001965 A PE2019001965 A PE 2019001965A PE 20191656 A1 PE20191656 A1 PE 20191656A1
- Authority
- PE
- Peru
- Prior art keywords
- ip6k
- inhibitors
- compound
- salts
- refers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017066579 | 2017-03-30 | ||
| PCT/JP2018/014502 WO2018182051A1 (en) | 2017-03-30 | 2018-03-29 | Ip6k inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191656A1 true PE20191656A1 (es) | 2019-11-07 |
Family
ID=62134158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001965A PE20191656A1 (es) | 2017-03-30 | 2018-03-29 | Inhibidores de ip6k |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10968178B2 (https=) |
| EP (1) | EP3601256A1 (https=) |
| JP (1) | JP7063915B2 (https=) |
| KR (1) | KR102597117B1 (https=) |
| CN (1) | CN110461828B (https=) |
| AR (1) | AR111307A1 (https=) |
| AU (1) | AU2018246053B2 (https=) |
| CA (1) | CA3057821A1 (https=) |
| CL (1) | CL2019002662A1 (https=) |
| CO (1) | CO2019012125A2 (https=) |
| EA (1) | EA038177B1 (https=) |
| EC (1) | ECSP19077969A (https=) |
| IL (1) | IL269347B2 (https=) |
| JO (1) | JOP20180029A1 (https=) |
| MA (1) | MA49006A (https=) |
| MX (1) | MX393896B (https=) |
| NZ (1) | NZ758061A (https=) |
| PE (1) | PE20191656A1 (https=) |
| PH (1) | PH12019502248A1 (https=) |
| SG (1) | SG11201908894SA (https=) |
| TW (1) | TWI778038B (https=) |
| UA (1) | UA125445C2 (https=) |
| WO (1) | WO2018182051A1 (https=) |
| ZA (1) | ZA201907136B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE064141T2 (hu) | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| EP4146648A1 (en) * | 2020-05-04 | 2023-03-15 | Otsuka Pharmaceutical Co., Ltd. | Iap antagonist compounds and intermediates and methods for synthesizing the same |
| UY39609A (es) * | 2021-01-12 | 2022-08-31 | Servier Lab | Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos |
| US20250154115A1 (en) * | 2022-02-11 | 2025-05-15 | The University Of North Carolina At Chapel Hill | Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof |
| CN115747325A (zh) * | 2022-11-10 | 2023-03-07 | 上海交通大学医学院附属新华医院 | Ip6k1及其产物作为增加血液脂联素药物靶点的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) * | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| US7045527B2 (en) | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
| AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| TW200740435A (en) | 2005-08-10 | 2007-11-01 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| RS53230B (sr) | 2006-06-27 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| RU2454415C9 (ru) | 2006-10-19 | 2013-02-27 | Такеда Фармасьютикал Компани Лимитед | Производное индола |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| JP2010517935A (ja) | 2007-02-09 | 2010-05-27 | 武田薬品工業株式会社 | Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物 |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (en) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Indazole compounds for activating glucokinase |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
-
2018
- 2018-03-28 AR ARP180100763A patent/AR111307A1/es active IP Right Grant
- 2018-03-29 MA MA049006A patent/MA49006A/fr unknown
- 2018-03-29 JP JP2019554003A patent/JP7063915B2/ja active Active
- 2018-03-29 MX MX2019011783A patent/MX393896B/es unknown
- 2018-03-29 PE PE2019001965A patent/PE20191656A1/es unknown
- 2018-03-29 JO JOP/2018/0029A patent/JOP20180029A1/ar unknown
- 2018-03-29 EA EA201992306A patent/EA038177B1/ru unknown
- 2018-03-29 NZ NZ758061A patent/NZ758061A/en unknown
- 2018-03-29 CA CA3057821A patent/CA3057821A1/en active Pending
- 2018-03-29 KR KR1020197031524A patent/KR102597117B1/ko active Active
- 2018-03-29 CN CN201880022971.2A patent/CN110461828B/zh active Active
- 2018-03-29 IL IL269347A patent/IL269347B2/en unknown
- 2018-03-29 UA UAA201910745A patent/UA125445C2/uk unknown
- 2018-03-29 EP EP18723386.1A patent/EP3601256A1/en active Pending
- 2018-03-29 TW TW107110992A patent/TWI778038B/zh active
- 2018-03-29 US US16/496,530 patent/US10968178B2/en active Active
- 2018-03-29 SG SG11201908894S patent/SG11201908894SA/en unknown
- 2018-03-29 WO PCT/JP2018/014502 patent/WO2018182051A1/en not_active Ceased
- 2018-03-29 AU AU2018246053A patent/AU2018246053B2/en active Active
-
2019
- 2019-09-16 CL CL2019002662A patent/CL2019002662A1/es unknown
- 2019-09-27 PH PH12019502248A patent/PH12019502248A1/en unknown
- 2019-10-29 CO CONC2019/0012125A patent/CO2019012125A2/es unknown
- 2019-10-29 ZA ZA2019/07136A patent/ZA201907136B/en unknown
- 2019-10-30 EC ECSENADI201977969A patent/ECSP19077969A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191656A1 (es) | Inhibidores de ip6k | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PY1906086A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
| PY1909256A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR070130A1 (es) | Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento | |
| SV2016005312A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cã�ncer | |
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| UY37703A (es) | Compuestos heteroarílicos bicíclicos 6-6 fusionados y su uso como inhibidores de lats | |
| AR111242A1 (es) | Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
| CO2017002292A2 (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| WO2016081203A3 (en) | Phospholipid ether analogs as cancer-targeting drug vehicles | |
| AR088983A1 (es) | Procedimiento para la preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| AR090376A1 (es) | Compuestos herbicidas | |
| PE20190414A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| MX2021015188A (es) | Moduladores de nueva generacion del estimulador de genes de interferon (sting). | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| MX2019013816A (es) | Compuesto usado como regulador de la autofagia, metodo de preparacion y sus usos. | |
| AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre | |
| MX2017011650A (es) | Inhibidores de kv1.3 y su aplicacion medica. | |
| MX384293B (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefálica |